[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-340107-en":59,"doc-seo-340107-105":99},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":72,"language":73,"language_code":74,"site_id":75,"html_lang":74,"table_of_contents":76,"faqs":77,"seo_title":78,"seo_description":66,"update_tm":79,"read_time":80,"preview_page_count":19,"preview_urls":81},340107,1374391975076,"Riley","https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","The immune response to Covid-19 mRNA vaccination among Lymphoma patients receiving anti-CD20 treatment","mRNA COVID-19 vaccination is critical for lymphoma patients due to age and comorbidities that increase risk of poor outcomes after SARS-CoV-2 infection. Anti-CD20 therapy with rituximab depletes B-cell populations and may impair vaccine efficacy. A cohort of 28 rituximab-treated, CD20-positive lymphoma patients who received vaccination including boosters was followed to assess vaccine take in humoral (IgG, IgA) and cellular compartments, and compared with healthy controls.","TYPE Original Research PUBLISHED 04 September 2024 DOI 10.3389/fimmu.2024.1433442  \nOPEN ACCESS  \nEDITED BY  \nConstantino Lo´ pez-Macas,  \nMexican Social Security Institute, Mexico  \nREVIEWED BY  \nMarco Jimenez Ochoa,  \nMexican Social Security Institute, Mexico Güliz Tuba Barut,  \nInstitute of Virology and Immunology, Switzerland  \n*CORRESPONDENCE Maximillian Rosario  \n [mrosari8@jhmi.edu](mrosari8@jhmi.edu)  \n†These authors have contributed equally to this work  \nRECEIVED 15 May 2024  \nACCEPTED 15 July 2024  \nPUBLISHED 04 September 2024  \nCITATION  \nKomlodi-Pasztor E, Escarra-Senmarti M, Bazer DA, Bhatnagar A, Perez Heydrich CA, Messmer M, Ambinder RF, Gladstone DE, Clayton L, Goodrich A, Schoch L, Wagner-Johnston N, VandenBussche CJ, Huang P, Holdhoff M and Rosario M (2024) The immune response to Covid-19 mRNA vaccination among Lymphoma patients receiving anti-CD20 treatment.  \nFront. Immunol. 15:1433442 .  \ndoi: 10.3389/fimmu.2024.1433442  \nCOPYRIGHT  \n© 2024 Komlodi-Pasztor, Escarra-Senmarti, Bazer, Bhatnagar, Perez Heydrich, Messmer, Ambinder, Gladstone, Clayton, Goodrich, Schoch, Wagner-Johnston, VandenBussche, Huang, Holdhoff and Rosario. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nThe immune response to Covid- 19 mRNA vaccination among Lymphoma patients receiving anti-CD20 treatment  \nEdina Komlodi-Pasztor 1,2, Marta Escarra-Senmarti 3, Danielle A. Bazer 1, Aastha Bhatnagar 2,  \nCarlos A. Perez Heydrich 1, Marcus Messmer 1,4,  \nRichard F. Ambinder 1, Douglas E. Gladstone 1,5, Laura Clayton 1, Amy Goodrich 1, Laura Schoch 1, Nina Wagner-Johnston 1, Christopher J. VandenBussche 1,3, Peng Huang 1,  \nMatthias Holdhoff 1† and Maximillian Rosario 3*†  \n1 Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States,  \n2 Department of Neurology, MedStar Georgetown University Hospital, Washington, DC, United States,  \n3 Department of Pathology, Division of Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, United States, 4 Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, United States, 5 Northwell Health Cancer Institute, New Hyde Park, NY, United States  \nThe monoclonal antibody rituximab improves clinical outcome in the treatment of CD20-positive lymphomatous neoplasms, and it is an established drug for treatment of these cancers . Successful mRNA COVID-19 (SARS-CoV-2) vaccination is extremely important for lymphoma patients because they tend to be elderly with comorbidities which leaves them at increased risk of poor outcomes once infected by Coronavirus. Anti-CD20 therapies such as rituximab, deplete B-cell populations and can affect vaccine efﬁcacy. Therefore, a knowledge of the effect of COVID-19 vaccination in this group is critical. We followed a cohort of 28 patients with CD20-positive lymphomatous malignancies treated with rituximab that started prior to their course of COVID-19 vaccination, including boosters. We assayed for vaccine “take” in the humoral (IgG and IgA) and cellular compartment. Here, we show that short-term and long-term development of IgG and IgA antibodies directed toward COVID- 19 spike protein are reduced in these patients compared to healthy controls. Conversely, the robustness and breath of underlying T-cell response is equal to healthy controls. This response is not limited to speciﬁc parts of the spike protein but spans the spike region, including response to the conserved Receptor Binding Domain (RBD) . Our data informs on rational vaccine design and bodeswell for future vaccination strategies that ","cbCaijrPoy407jg4","https://ap.wps.com/l/cbCaijrPoy407jg4","pdf",1125709,11,"English","en",105,"# Highlights\n## B-cell and T-cell response findings\n# Introduction\n## Vaccination and SARS-CoV-2\n## Anti-CD20 therapy and immune modulation","[{\"question\":\"Why is COVID-19 mRNA vaccination important for lymphoma patients?\",\"answer\":\"Lymphoma patients are often elderly and have comorbidities, leaving them at higher risk of poor outcomes after infection. Vaccination is presented as a key way to reduce severe disease risk.\"},{\"question\":\"How does rituximab treatment affect vaccine-induced antibodies in these patients?\",\"answer\":\"Short-term and long-term development of IgG and IgA antibodies against the COVID-19 spike protein is reduced compared with healthy controls.\"},{\"question\":\"Do T-cell responses differ between rituximab-treated lymphoma patients and healthy controls?\",\"answer\":\"The robustness and breadth of underlying T-cell responses are reported as equal to those in healthy controls, spanning the spike region including the conserved RBD.\"}]","The immune response to Covid-19 mRNA vaccination among Lymphoma patients receiving anti-CD20 treatment | PDF",1790034199,28,[82,86,90,95],{"page_no":8,"url":83,"width":84,"height":85},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/867abf9b6462b1c274643ec8aa7c49e2.webp",983,1389,{"page_no":14,"url":87,"width":88,"height":89},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f347d5bdbe6d5e55a784ce748cb118eb.webp",982,1388,{"page_no":91,"url":92,"width":93,"height":94},3,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64e91d0f7834a97bb820a11d75fda54c.webp",981,1386,{"page_no":19,"url":96,"width":97,"height":98},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa88af1f9f0ad7682bf9148420a95394.webp",980,1385,{"code":4,"msg":100,"data":101},"ok",{"site_id":75,"language":74,"slug":102,"title":65,"keywords":103,"description":66,"schema_data":104,"social_meta":157,"head_meta":159,"extra_data":161,"updated_unix":162},"the-immune-response-to-covid-19-mrna-vaccination-among-lymphoma-patients-receiving-anti-cd20-treatment","",{"@graph":105,"@context":156},[106,119,139],{"@type":107,"itemListElement":108},"BreadcrumbList",[109,113,115,117],{"item":110,"name":111,"@type":112,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":114,"name":9,"@type":112,"position":14},"https://docshare.wps.com/document/",{"item":116,"name":40,"@type":112,"position":91},"https://docshare.wps.com/document/research-report/",{"item":118,"name":65,"@type":112,"position":19},"https://docshare.wps.com/document/the-immune-response-to-covid-19-mrna-vaccination-among-lymphoma-patients-receiving-anti-cd20-treatment/340107/",{"url":118,"name":65,"@type":120,"image":121,"author":126,"headline":65,"publisher":128,"fileFormat":131,"inLanguage":74,"description":66,"dateModified":132,"datePublished":133,"encodingFormat":131,"isAccessibleForFree":134,"interactionStatistic":135},"DigitalDocument",{"url":122,"@type":123,"width":124,"height":125},"https://docshare.wps.com/thumbnails/the-immune-response-to-covid-19-mrna-vaccination-among-lymphoma-patients-receiving-anti-cd20-treatment/340107.png","ImageObject",300,407,{"name":63,"@type":127},"Person",{"url":110,"name":129,"@type":130},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":136,"interactionType":137,"userInteractionCount":34},"InteractionCounter",{"@type":138},"ViewAction",{"@type":140,"mainEntity":141},"FAQPage",[142,148,152],{"name":143,"@type":144,"acceptedAnswer":145},"Why is COVID-19 mRNA vaccination important for lymphoma patients?","Question",{"text":146,"@type":147},"Lymphoma patients are often elderly and have comorbidities, leaving them at higher risk of poor outcomes after infection. Vaccination is presented as a key way to reduce severe disease risk.","Answer",{"name":149,"@type":144,"acceptedAnswer":150},"How does rituximab treatment affect vaccine-induced antibodies in these patients?",{"text":151,"@type":147},"Short-term and long-term development of IgG and IgA antibodies against the COVID-19 spike protein is reduced compared with healthy controls.",{"name":153,"@type":144,"acceptedAnswer":154},"Do T-cell responses differ between rituximab-treated lymphoma patients and healthy controls?",{"text":155,"@type":147},"The robustness and breadth of underlying T-cell responses are reported as equal to those in healthy controls, spanning the spike region including the conserved RBD.","https://schema.org",{"og:url":118,"og:type":158,"og:title":65,"og:site_name":129,"og:description":66},"article",{"robots":160,"canonical":118},"index,follow",{"doc_id":61,"site_id":75},1790170846]